|
| Title |
Pub. Date |
Int. Class |
App. Num |
Applicant |
| 1. |
(WO 2007/104062) COMPOSITIONS AND METHODS BASED ON PEPTIDE BINDING PROFILING
|
13.09.2007
|
C12Q 1/00
|
PCT/US2007/063736
|
THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
|
| |
Methods and compositions are described for classifying cells and/or peptides that associate or bind with a particular characteristic pattern to a plurality of cells or cell lines. Aspects of the invention also include the use of peptide(s) having an appropriate binding characteristic to deliver a drug to a cell or cell population.
|
| |
|
| 2. |
(WO 2007/104058) METHOD AND APPARATUS FOR TARGET DETECTION USING ELECTRODE-BOUND VIRUSES
|
13.09.2007
|
C12Q 1/70
|
PCT/US2007/063723
|
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
|
| |
A biosensor capable of detecting the presence and/or concentration of an analyte or biomarker includes at least one electrically conductive electrode operatively coupled to an impedance analyzer for measuring the change in the resistive impedance of the electrode in response to an applied alternating current at a plurality of frequencies. In one embodiment, at least one electrode is covered with a self-assembled monolayer that is chemically bonded to a surface. A plurality of virus particles such as phage viruses are immobilized on the self-assembled monolayer and may be exposed to a test or sample solution. The virus particles may be obtained from phage-displayed libraries to detect a wide variety of targets including, for example, DNA, RN...
|
| |
|
| 3. |
(WO 2007/104049) COMPLEX AMPLITUDE MODULATION IN BLOOD FLOW AND PERFUSION MEASUREMENT
|
13.09.2007
|
G01V 3/00
|
PCT/US2007/063691
|
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
|
| |
Systems and methods for blood flow and perfusion measurement using complex amplitude modulation of MRI pulses are presented. In exemplary embodiments of the disclosed subject matter, inflowing arterial spins can be modulated using a complex modulation function having certain mathematical properties in the frequency domain, such as, for example, a pseudo-random sequence. In exemplary embodiments of the disclosed subject matter the mathematical properties of such complex modulation functions can be used to measure individual transit times by deconvolving them from a series of acquired images. In exemplary embodiments of the disclosed subject matter images can be acquired at the same rapid rate as arterial modulation, and transit time distribu...
|
| |
|
| 4. |
(WO 2007/104028) MULTI-JUNCTION SOLAR CELLS WITH A HOMOGENIZER SYSTEM AND COUPLED NON-IMAGING LIGHT CONCENTRATOR
|
13.09.2007
|
H01L 31/042
|
PCT/US2007/063609
|
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
|
| |
Optical systems and methods that concentrate light from a distant source, such as the sun, onto a target device, such as a solar cell. Light impinging from the distant source, is focused or imaged by a plurality of primary reflective segments of a primary mirror element onto a plurality of corresponding secondary reflective segments. The secondary mirror segments image the corresponding primary segments onto an exit aperture such that the exit aperture is uniformly illuminated. A target cell may be located proximal to the exit aperture, or an entry aperture of a non-imaging concentrator may be positioned proximal the exit aperture, wherein the concentrator concentrates the reflected light onto the target cell.
|
| |
|
| 5. |
(WO 2007/104019) HYBRID PROTEIN WITH COX AND PGES ENZYME ACTIVITIES
|
13.09.2007
|
C12P 21/04
|
PCT/US2007/063590
|
BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
|
| |
A representative hybrid or engineered protein is constructed by linking together human cyclooxygenase (COX) isoform-2 (COX-2) and prostaglandin E<sb>2</sb> synthase (PGES) via a 10-20 amino acid residues of a transmembrane sequence. The single protein molecule is expressed in cells, and adopts the functions of COX and PGES, to continually convert arachidonic acid (AA) into prostaglandin G<sb>2</sb> (catalytic step 1), prostaglandin H<sb>2</sb> (catalytic step 2) and prostaglandin E<sb>2</sb> (PGE<sb>2</sb>; catalytic step 3). The COX-2-10aa-mPGES hybrid protein also converts dihomo-γ- linolenic acid (DGLA) into PGE<sb>1</...
|
| |
|
| 6. |
(WO 2007/104011) INHIBITION OF MICROTUBULE PROTRUSION IN CANCER CELLS
|
13.09.2007
|
A61K 31/33
|
PCT/US2007/063566
|
UNIVERSITY OF MARYLAND, BALTIMORE
|
| |
The present invention generally concerns microtubule protrusions in cancer cells, including detached cancer cells, and inhibition of the protrusions. In particular aspects, the inhibition of the protrusions interferes with attachment of the cell to a vessel wall, and in further aspects the cell is killed by forcing it to enter capillaries and be destroyed, for example by shearing. Inhibition by a variety of agents and methods is contemplated.
|
| |
|
| 7. |
(WO 2007/104000) HYBRID PROTEIN THAT CONVERTS ARACHIDONIC ACID INTO PROSTACYCLIN
|
13.09.2007
|
C12P 21/04
|
PCT/US2007/063542
|
BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
|
| |
A recombinant 130-kDa protein is constructed by linking together human cyclooxygenase (COX) isoform-2 (COX-2) and prostacyclin synthase (PGIS), via a 10-20 amino acid residues of a transmembrane sequence. The engineered protein is expressed in cells, and adopts the functions of COX and PGIS, to continually convert arachidonic acid (AA) into prostaglandin G2 (catalytic step 1), prostaglandin H2 (catalytic step 2) and prostacyclin (PGI2; catalytic step 3).
|
| |
|
| 8. |
(WO 2007/103988) COMPOSITIONS AND METHODS FOR DETECTION AND TREATMENT OF HUMAN HERPESVIRUS (HHV)-6
|
13.09.2007
|
C12N 15/11
|
PCT/US2007/063514
|
UNIVERSITY OF ROCHESTER
|
| |
Disclosed herein are compositions and methods for detection and treatment of human herpesvirus (HHV)-6.
|
| |
|
| 9. |
(WO 2007/103910) SPECIFIC AMPLIFICATION OF FETAL DNA SEQUENCES FROM A MIXED, FETAL-MATERNAL SOURCE
|
13.09.2007
|
C12Q 1/68
|
PCT/US2007/063366
|
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY Of NEW YORK
|
| |
The present invention provides a method of selectively amplifying fetal DNA sequences from a mixed, fetal-maternal source. This method utilizes differential methylation to allow for the selective amplification of trophoblast/fetal specific sequences from DNA mixtures that contain a high proportion of non- trophoblast/fetal DNA. The invention also provides methods of using the amplified fetal DNA sequences for aneuploidy detection.
|
| |
|
| 10. |
(WO 2007/103876) CANCER THERAPEUTIC
|
13.09.2007
|
C07H 21/02
|
PCT/US2007/063318
|
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
|
| |
Methods for the delivery of a siNA to a cell via a liposome are provided. In certain embodiments, the siNA may bind to a nucleotide sequence encoding ZNF306 protein. These methods may be used to treat a disease, such as cancer. One example of a composition is a composition comprising a siNA component that binds to a nucleotide sequence encoding ZNF306 protein and a lipid component. One example of a method is a method of treating cancer.
|
| |
|
| 11. |
(WO 2007/103875) SYSTEMS AND METHODS FOR REDUCING WATER CONTAMINATION
|
13.09.2007
|
C02F 3/12
|
PCT/US2007/063317
|
SAM HOUSTON STATE UNIVERSITY
|
| |
In some embodiments, a system may reduce contaminants in water. A system may include a biofilm in a container. The biofilm may be formed from one or more bacteria coupled to one or more substrates. The bacteria may be selected to maximize the reduction of contaminants in water. The system may include one or more bacteria generators to provide bacteria to the biofilm and/or one or more air sources to provide an air bubble stream to the container and/or the bacteria generator. In some embodiments, bacteria may be preserved in a starvation phase. Bacteria may be incubated until they reach a starvation phase. The bacteria may then be preserved as beads or immobilized on a substrate. The preserved bacteria may be used in a system for the reducti...
|
| |
|
| 12. |
(WO 2007/103832) FUEL-POWERED ACTUATORS AND METHODS OF USING SAME
|
13.09.2007
|
F02C 1/00
|
PCT/US2007/063241
|
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
|
| |
Fuel-powered actuators are described wherein actuation is a consequence of electrochemical processes, chemical processes, or combinations thereof. These fuel-powered actuators include artificial muscles and actuators in which actuation is non-mechanical. The actuators range from large actuators to microscopic and nanoscale devices.
|
| |
|
| 13. |
(WO 2007/103828) FLUOROCYTIDINE DERIVATIVES AND COX-2 INHIBITORS FOR THE TREATMENT OF CANCER
|
13.09.2007
|
A61K 31/7072
|
PCT/US2007/063236
|
THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
|
| |
The present invention provides, in certain embodiments, methods for the treatment of colorectal cancer comprising administering a COX-2 inhibitor and fluorocytidine derivative to a human patient. In certain embodiments, a radiation therapy is also administered to the patient.
|
| |
|
| 14. |
(WO 2007/103825) COMBINATION THERAPY WITH ONCOLYTIC ADENOVIRUS
|
13.09.2007
|
A01N 63/00
|
PCT/US2007/063232
|
THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
|
| |
The present invention involves compositions and methods for treating cancer using a combinatin of cell cycle modulating agent(s) and anticancer agents or therapies, particularly S-phase specific therapies.
|
| |
|
| 15. |
(WO 2007/103823) GENETIC MARKERS FOR PREDICTING DISEASE AND TREATMENT OUTCOME
|
13.09.2007
|
C12Q 1/68
|
PCT/US2007/063230
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
| |
The present invention provides for a method for identifying patients that are suitably treated by a therapy, such as a therapy involving administration of a fluoropyrimidine drug and/or a platinum drug. The method includes determining the expression level of at least one gene selected from a phospholipase 2 (PLA2) gene, a thymidine phosphorylase (TP) gene, and a glutathione S-transferase P1 (GSTP-1) gene in suitable sample isolated from the patient. Overexpression of the gene or genes identifies the patient as not being suitable for the therapy.
|
| |
|
| 16. |
(WO 2007/103816) POLYMORPHISMS IN VOLTAGE-GATED SODIUM CHANNEL ALPHA 1-SUBUNIT AS MARKERS FOR THERAPY SELECTION
|
13.09.2007
|
C12Q 1/68
|
PCT/US2007/063219
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
| |
A method for determining whether a patient in need thereof will respond to chemotherapy by screening a suitable sample isolated from the patient for a pre-selected polymorphism present in the VGSC gene.
|
| |
|
| 17. |
(WO 2007/103814) ANGIOGENESIS PATHWAY GENE POLYMORPHISMS FOR THERAPY SELECTION
|
13.09.2007
|
A61K 39/395
|
PCT/US2007/063216
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
| |
A method for determining whether a patient in need thereof will respond to anti-VEGF antibody based chemotherapy by screening a suitable cell or tissue sample isolated from the patient for at least one genomic polymorphism or genotype selected from (i) IL 8( -251); (ii) VEGF(936); or (iii) AM (3' CA repeats), wherein the patient is suitably treated if the corresponding genotype is (i) (T/T) for IL-8(-251); (ii) (T/T or C/T) for VEGF(936); or (iii) at least one AM allele having 14 or more 3'CA repeats.
|
| |
|
| 18. |
(WO 2007/103808) MICRORNA EXPRESSION PROFILE ASSOCIATED WITH PANCREATIC CANCER
|
13.09.2007
|
C12Q 1/68
|
PCT/US2007/063208
|
THE OHIO STATE UNIVERSITY
|
| |
Methods are provided for diagnosing whether a subject has, or is at risk of developing, pancreatic cancer. The methods include measuring the level of at least one miR gene product in a biological sample derived from the subject's pancreas. An alteration in the level of the miR gene product in the biological sample as compared to the level of a corresponding miR gene product in a control sample, is indicative of the subject either having, or being at risk for developing, pancreatic cancer.
|
| |
|
| 19. |
(WO 2007/103802) NANORICE PARTICLES: HYBRID PLASMONIC NANOSTRUCTURES
|
13.09.2007
|
G01N 21/55
|
PCT/US2007/063201
|
WILLIAM MARSH RICE UNIVERSITY
|
| |
A new hybrid nanoparticle, i.e., a nanorice particle, which combines the intense local fields of nanorods with the highly tunable plasmon resonances of nanoshells, is described herein. This geometry possesses far greater structural tunability than previous nanoparticle geometries, along with much larger local field enhancements and far greater sensitivity as a surface plasmon resonance (SPR) nanosensor than presently known dielectric-conductive material nanostructures. In an embodiment, a nanoparticle comprises a prolate spheroid-shaped core having a first aspect ratio. The nanoparticle also comprises at least one conductive shell surrounding said prolate spheroid-shaped core. The nanoparticle has a surface plasmon resonance sensitivity of ...
|
| |
|
| 20. |
(WO 2007/103792) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND IMMUNOTHERAPY OF POLLEN ALLERGY
|
13.09.2007
|
C12N 9/50
|
PCT/US2007/063188
|
THE UNIVERSITY OF CHICAGO
|
| |
A diagnostic pollen array includes allergens extracted from pollen coat material. Diagnostic pollen arrays are useful to diagnose allergy in individuals, identify novel allergens, identify genetic loci responsible for allergy in hosts, and to develop treatment plans for allergy.
|
| |
|
| 21. |
(WO 2007/103788) YEAST REPORTER SYSTEM BASED ON FUSION PROTEINS OF SUP35P
|
13.09.2007
|
G01N 33/50
|
PCT/US2007/063178
|
THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
|
| |
Cell-based screens for compounds that inhibit the accumulation of amyloids are described. For example, the herein described screens may be used to assay the formation, or inhibition, of pre- amyloid or amyloid aggregates and/or oligomers. Agents have been identified that interfere with, or inhibit, the oligomerization of the major component of amyloid plaques; a 42 amino acid long Aβ42 peptide product of proteolytic processing of the APP protein.
|
| |
|
| 22. |
(WO 2007/103778) METHOD AND SYSTEM FOR ASSESSING REPOLARIZATION ABNORMALITIES
|
13.09.2007
|
A61B 5/0468
|
PCT/US2007/063150
|
UNIVERSITY OF ROCHESTER
|
| |
A method for assessing repolarization abnormalities is disclosed. At least two repolarization signals are identified from a set of ECG signals. PCA analysis is performed on the at least two repolarization signals to extract at least eigenvectors ev1 and ev2. A maximum vector MV is determined based on a transformed ECG signal in a plane defined by ev1 and ev2. A repolarization duration is determined which is based on the maximum vector MV. A system for assessing repolarization abnormalities is also disclosed. The system has a processor configured to determine a repolarization duration which is based on a maximum vector MV from transformed ECG repolarization signals in a plane defined by eigenvectors ev1 and ev2 which result from PCA analysis...
|
| |
|
| 23. |
(WO 2007/103775) BIOMATERIALS HAVING NANOSCALE LAYERS AND COATINGS
|
13.09.2007
|
A61K 9/14
|
PCT/US2007/063142
|
WASHINGTON UNIVERSITY IN ST. LOUIS
|
| |
The invention generally relates to substrates and surfaces having substrates. Generally speaking, the substrates may be thinly layered substrates, and the surfaces may comprise thinly layered substrates. Additionally, the substrates may comprise a multifunctional water soluble polymer and a lipoprotein and the surfaces may comprise a multifunctional water soluble polymer and a lipoprotein.
|
| |
|
| 24. |
(WO 2007/103767) ROLE OF MICRORNA IN PLANT SALT TOLERANCE
|
13.09.2007
|
C12N 15/82
|
PCT/US2007/063131
|
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
|
| |
The present invention provides nucleic acid constructs encoding microRNA molecules that can be used to confer salt tolerance on plants. The invention further provides transgenic plants comprising the nucleic acids, as well as methods of using them to confer salt tolerance on plants.
|
| |
|
| 25. |
(WO 2007/103762) COMPOSITIONS AND METHODS OF USE OF ELECTRON TRANSPORT SYSTEM INHIBITORS
|
13.09.2007
|
A01N 25/00
|
PCT/US2007/063122
|
COLORADO STATE UNIVERSITY RESEARCH FOUNDATION
|
| |
The invention provides compounds of the formula: or a pharmaceutically acceptable salt thereof, where m, n, R1, R2, R3 R4, R5, R6, R7 are those defined herein. The invention also provides pharmaceutical compositions comprising a compound of the invention, methods for using compounds and/or pharmaceutical compositions of the invention, and methods for synthesizing compounds of the invention.
|
| |
|
![[Back to Top]](/ipdl/include/backtop.gif){kind=small}
